Sera Prognostics Presenting at Major Healthcare Conference
Sera Prognostics Inc., known as The Pregnancy Company® (NASDAQ: SERA), is dedicated to transforming maternal and neonatal healthcare through innovative biomarker solutions. Recently, the company announced its participation in an important healthcare event where it will share the latest advancements and achievements in pregnancy health. The conference is scheduled for December 5, with Zhenya Lindgardt, the President and CEO, addressing attendees in a fireside chat format. This presentation aims to provide valuable insights into Sera's ongoing commitment to improving pregnancy outcomes.
Importance of Biomarkers in Pregnancy Health
The ability to offer early and accurate information is pivotal in maternal health care. Sera Prognostics focuses on providing clinicians and expectant mothers with critical pregnancy biomarker information. Their innovative tests, particularly the PreTRM® Test, are designed to predict the risk of premature birth and related complications. This allows health care providers to take timely and appropriate actions, ultimately enhancing the health and safety of mothers and their newborns.
Understanding Preterm Birth
Preterm birth, defined as birth before 37 weeks' gestation, poses serious health risks for infants and represents a significant challenge in maternal healthcare. Statistics reveal that over ten percent of infants are born prematurely, which contributes to long-term health complications such as learning disabilities and chronic respiratory issues. The costs associated with managing these complications are staggering, highlighting the urgent need for improved predictive measures like those offered by Sera Prognostics.
Innovative Testing with the PreTRM® Test
The PreTRM® Test stands out as a leading diagnostic tool, being the first blood-based biomarker test available for early risk prediction of spontaneous preterm birth. By analyzing specific proteins in a mother's blood, the PreTRM® Test accurately identifies those who are at an increased risk during their pregnancy. This empowers healthcare professionals to make informed decisions and instigate preventative care measures, significantly aiding at-risk pregnancies.
Strategic Directions and Future Goals
Sera Prognostics is committed to maintaining a robust pipeline of diagnostic tests aimed at addressing pressing issues in prenatal care. Their approach is anchored in precision medicine, aiming to deliver tailored healthcare solutions. As they prepare for the upcoming conference, the company's focus remains on engaging with stakeholders to discuss their latest innovations and explore potential collaborations in advancing maternal health.
Frequently Asked Questions
What is Sera Prognostics?
Sera Prognostics is a health diagnostics company that specializes in innovative pregnancy-related biomarker information to enhance maternal and neonatal health outcomes.
What is the PreTRM® Test?
The PreTRM® Test is a blood-based biomarker test that provides early risk predictions for spontaneous preterm birth, helping healthcare providers make proactive decisions.
Why is preterm birth a critical issue?
Preterm birth is a leading cause of illness and death among newborns, resulting in significant health complications and healthcare costs.
Who will present at the healthcare conference?
Zhenya Lindgardt, the President and CEO of Sera Prognostics, will present at the conference, discussing the company's achievements and innovations.
What is Sera's mission?
Sera's mission is to provide pivotal pregnancy information that improves the lives of mothers and babies, reducing healthcare costs and risks associated with pregnancy complications.
